Cel-Sci Submits Scientific Advice Filing To European Medicines Agency For Multikine In The Treatment Of Head And Neck Cancer
Portfolio Pulse from Benzinga Newsdesk
Cel-Sci has submitted a scientific advice filing to the European Medicines Agency for Multikine in the treatment of head and neck cancer. Europe sees 150,000 new cases of this type of cancer each year, more than twice the incidence in the U.S.
September 26, 2023 | 1:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cel-Sci's submission to the European Medicines Agency for Multikine could potentially open up a large market in Europe, where the incidence of head and neck cancer is more than twice that in the U.S.
The news of Cel-Sci's submission to the European Medicines Agency for Multikine is directly relevant to the company and its stock. If approved, it could open up a large market in Europe for the company, potentially leading to increased revenues and a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100